1. Medicines
  2. Respiratory and Inflammation
  3. ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder)
  4. References
  5. FACT SHEET FOR BUHL R et al. 2019

Prescribing information

 

FACT SHEET FOR BUHL R et al. 2019

Indication: ENERZAIR BREEZHALER is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.1

Please contact a Novartis representative to order this material.

Reference

  1. ENERZAIR BREEZHALER Summary of Product Characteristics.
ENE20-C007 November 2020.
Respiratory and Inflammation
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]